Texas-based diagnostics company Volition Veterinary has announced the results of a proof of concept study for its Nu.Q Vet Assay which found that a single assay detected almost 70% of both canine hemangiosarcoma and canine lymphoma

Together, these two cancers account for almost a third of all canine cancers. 

Dr. Heather Wilson-Robles, an Associate Professor at Texas A&M University and Chief Medical Officer of Volition Veterinary Diagnostics said: "The proof of concept results in these two very prevalent canine cancers give us confidence to move forward with other Nu.Q Vet assays in our pipeline, and with the larger range of cohorts and trials we have collected and planned.

"Clearly, we still have work to do as this single assay did not detect one of the other top five canine cancers, canine osteosarcoma, which was the third cancer tested in this study. However, I am delighted to see such positive results in these two significant cancers and look forward to reporting further data over the coming quarters with additional Nu.Q Vet assays, this time tested on an automated platform.”

Dr. Terry Kelly, Chief Scientific Officer of Volition America said: “It is exciting to see such strong results from our first Nu.Q Vet study conducted at Texas A&M University Veterinary Hospital. It is also interesting to note the similar patterns of detection seen in both canine and human samples confirming that the Nu.Q platform does appear to be useful in more than just human diagnostics.

"As with human diagnostics, there are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. I look forward to completing the planned trials and to launch our first Nu.Q Vet product in the U.S. that we expect to occur in 2020."


Whilst you're here, take a moment to see our latest job opportunities for vets.